Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is CPI-818, an investigational, oral, small molecule drug that selectively inhibits ITK and is in a mid-stage clinical trial...
Data Provided by Refinitiv. Minimum 15 minutes delayed.
May 31, 2023
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 17, 2023
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
May 08, 2023
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results